Ge Long, Wang Qi, He Yihan, Wu Darong, Zhou Qi, Xu Nenggui, Yang Kehu, Chen Yaolong, Zhang Anthony Lin, Hua Haiqing, Huang Jinchang, Hui Ka-Kit, Liang Fanrong, Wang Linpeng, Xu Bin, Yang Yufei, Zhang Weimin, Zhao Baixiao, Zhu Bing, Guo Xinfeng, Xue Charlie Changli, Zhang Haibo
Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.
Evidence Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.
Chin Med. 2022 Jan 5;17(1):8. doi: 10.1186/s13020-021-00558-4.
This study aims to develop an evidence-based clinical practice guideline of acupuncture in the treatment of patients with moderate and severe cancer pain.
The development of this guideline was triggered by a systematic review published in JAMA Oncology in 2020. We searched databases and websites for evidence on patient preferences and values, and other resources of using acupuncture for treatment of cancer pain. Recommendations were developed through a Delphi consensus of an international multidisciplinary panel including 13 western medicine oncologists, Chinese medicine/acupuncture clinical practitioners, and two patient representatives. The certainty of evidence, patient preferences and values, resources, and other factors were fully considered in formulating the recommendations. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was employed to rate the certainty of evidence and the strength of recommendations.
The guideline proposed three recommendations: (1) a strong recommendation for the treatment of acupuncture rather than no treatment to relieve pain in patients with moderate to severe cancer pain; (2) a weak recommendation for the combination treatments with acupuncture/acupressure to reduce pain intensity, decrease the opioid dose, and alleviate opioid-related side effects in moderate to severe cancer pain patients who are using analgesics; and (3) a strong recommendation for acupuncture in breast cancer patients to relieve their aromatase inhibitor-induced arthralgia.
This proposed guideline provides recommendations for the management of patients with cancer pain. The small sample sizes of evidence limit the strength of the recommendations and highlights the need for additional research.
本研究旨在制定基于证据的针刺治疗中重度癌痛患者的临床实践指南。
本指南的制定源于2020年发表在《美国医学会肿瘤学杂志》上的一项系统评价。我们在数据库和网站上搜索了关于患者偏好和价值观的证据,以及使用针刺治疗癌痛的其他资源。通过包括13名西医肿瘤学家、中医/针灸临床医生和两名患者代表在内的国际多学科小组的德尔菲共识制定了建议。在制定建议时充分考虑了证据的确定性、患者偏好和价值观、资源及其他因素。采用推荐分级评估、制定和评价(GRADE)方法对证据的确定性和推荐的强度进行评级。
该指南提出了三项建议:(1)强烈建议采用针刺治疗而非不治疗来缓解中重度癌痛患者的疼痛;(2)对于正在使用镇痛药的中重度癌痛患者,弱推荐针刺/指压联合治疗以降低疼痛强度、减少阿片类药物剂量并减轻阿片类药物相关副作用;(3)强烈建议对乳腺癌患者采用针刺治疗以缓解其芳香化酶抑制剂引起的关节痛。
本拟议指南为癌痛患者的管理提供了建议。证据的小样本量限制了建议的强度,并突出了进一步研究的必要性。